CEO and Co-Founder
illumifyDx
illumifyDx utilizes optical spectroscopy to detect cancer recurrence at an earlier stage, enhancing diagnostic accuracy. The company aims to improve patient outcomes by providing timely insights that facilitate prompt clinical interventions.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Detecting cancer recurrence often relies on late-stage detection methods, which can limit treatment options and negatively impact patient outcomes. Current diagnostic approaches may lack the sensitivity needed to identify recurrence at its earliest stages.
Solution
illumifyDx employs optical spectroscopy to enable earlier and more accurate detection of cancer recurrence. By leveraging this technology, illumifyDx aims to provide clinicians with timely insights into a patient's condition, facilitating prompt and effective clinical interventions. This approach allows for the identification of recurrence at an earlier stage than traditional methods, potentially improving patient outcomes through timely treatment adjustments. The technology offers a non-invasive method for monitoring cancer recurrence, providing a valuable tool for oncologists and their patients.
Target Audience
The primary target audience includes oncologists and other healthcare professionals involved in cancer treatment and monitoring, as well as patients at risk of cancer recurrence.
Features
- Optical spectroscopy for early detection of cancer recurrence
- Enhanced diagnostic accuracy compared to traditional methods
- Non-invasive monitoring of cancer recurrence